Xenon Pharmaceuticals Inc - Asset Resilience Ratio
Xenon Pharmaceuticals Inc (XENE) has an Asset Resilience Ratio of 35.63% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Xenon Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check Xenon Pharmaceuticals Inc (XENE) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Xenon Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Xenon Pharmaceuticals Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $349.72 Million | 35.63% |
| Total Liquid Assets | $349.72 Million | 35.63% |
Asset Resilience Insights
- Very High Liquidity: Xenon Pharmaceuticals Inc maintains exceptional liquid asset reserves at 35.63% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Xenon Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Xenon Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Xenon Pharmaceuticals Inc (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Xenon Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.63% | $349.72 Million | $981.67 Million | -25.04pp |
| 2024-12-31 | 60.67% | $484.19 Million | $798.14 Million | +9.94pp |
| 2023-12-31 | 50.73% | $489.44 Million | $964.80 Million | -20.19pp |
| 2022-12-31 | 70.92% | $534.85 Million | $754.15 Million | +5.17pp |
| 2021-12-31 | 65.75% | $376.09 Million | $572.01 Million | -4.02pp |
| 2020-12-31 | 69.77% | $131.99 Million | $189.19 Million | -9.18pp |
| 2019-12-31 | 78.95% | $116.60 Million | $147.70 Million | +36.84pp |
| 2018-12-31 | 42.11% | $51.55 Million | $122.43 Million | -8.15pp |
| 2017-12-31 | 50.26% | $23.18 Million | $46.12 Million | -19.46pp |
| 2016-12-31 | 69.72% | $47.05 Million | $67.49 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $63.95 Million | -- |
| 2014-12-31 | 13.74% | $12.02 Million | $87.42 Million | -7.04pp |
| 2013-12-31 | 20.79% | $11.33 Million | $54.49 Million | -- |
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizure… Read more